Unicycive Therapeutics
UNCY
23 hedge funds and large institutions have $31.6M invested in Unicycive Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 0 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
179% more capital invested
Capital invested by funds: $11.3M → $31.6M (+$20.3M)
44% more funds holding
Funds holding: 16 → 23 (+7)
2.36% more ownership
Funds ownership: 3.75% → 6.11% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.21M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$2.28M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$1.81M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$124K |
UNCY Hedge Fund Activity: Q1 2024 in Review
23 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2024, worth a combined $31.6M — up 179% from $11.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new UNCY positions and 0 closed out — a net gain of 7 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $4.21M. The largest seller was Nantahala Capital Management, cutting an estimated $124K.
- 23 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2024, up from 16 in Q4 2023.
- Funds reported $31.6M of Unicycive Therapeutics stock for Q1 2024, up 179% quarter-over-quarter.
- 7 funds opened new Unicycive Therapeutics positions in Q1 2024 and 0 closed out, a net change of +7 holders.
- The largest Unicycive Therapeutics buyer in Q1 2024 was Logos Global Management, an estimated $4.21M added.
- The largest Unicycive Therapeutics seller in Q1 2024 was Nantahala Capital Management, an estimated $124K sold.
Based on aggregated 13F filings for Q1 2024.